Comparative effectiveness of calcium acetate and sevelamer on clinical outcomes in elderly hemodialysis patients enrolled in Medicare part D.

ABSTRACT:

Background

Phosphate binders are an important therapeutic option for managing hyperphosphatemia in hemodialysis patients. Whether sevelamer confers a survival advantage over calcium acetate is unclear.

Study design

Observational cohort study using US Renal Data System (USRDS) data linked to Medicare Part D prescription drug data.

Setting & participants

Medicare-enrolled elderly incident hemodialysis patients initiating calcium acetate or sevelamer therapy between July 1, 2006, and March 31, 2011.

Predictor

Prescription for sevelamer (hydrochloride or carbonate) or calcium acetate.

Outcomes & measurements

All-cause and cardiovascular-related mortality, hospital admissions and hospital days assessed from Medicare Parts A, B, and D claims and other USRDS da

SUBMITTER: Yusuf AA 

PROVIDER: S-EPMC4069228 | biostudies-literature | 2014 Jul

REPOSITORIES: biostudies-literature